Gelonghui, March 1 | Laimei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (“Laimei Longyu”), a wholly-owned subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., received the approval and issuance of Nicodyl (Specification: 4.00kg/bag, 1 bag/bottle) “Notice of Approval of Application for Chemical Ingredients” by the State Drug Administration.

Nicordil for injection is mainly used for unstable angina pectoris and acute heart failure, improves coronary microcirculation, can effectively reduce cardiovascular events, and can significantly reduce the risk of acute coronary syndrome. Clinical patients benefit a lot.